The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data…
Dementia can be isolating — for the person living with the disease, and for caregivers. It can also be generative. For a number of…
This article was made possible through sponsorship by Alzheon. Being Patient’s editorial team produced the interview with no review/approval process by the sponsor. Alzheimer’s…
UPDATE: 3 March 2024, 8:14 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Beta-amyloid plaques — sticky globs of protein — build up in the brains of people with Alzheimer’s disease. For decades, scientists have focused on…
It was 7:20 a.m. and Joel Braunstein, co-founder and CEO of C2N Diagnostics, was about to start his second meeting of the day. C2N…
Alzheimer’s disease affects one in every three people over the age of 85, and the scale of the epidemic is only worsening. While there…
This article is part of the series Diversity & Dementia, produced by Being Patient with support provided by Eisai. Some of the United States’s most widespread…
I’m writing from Amsterdam, where this past week, the Being Patient editorial team has been reporting on the biggest news from the Alzheimer’s Association…
AMSTERDAM —In the data presented at this week’s Alzheimer’s Association International Conference in Amsterdam, donanemab has been shown to slow development of memory and…
As I prepared to board the plane to Amsterdam for the Alzheimer’s Association International Conference, an email from the news site Axios caught my…
AMSTERDAM — When we arrived at the Rijks Museum, the home of Netherland’s most cherished artwork and cultural heritage, the halls were pretty empty…
Recently, Eli Lilly announced that their anti-amyloid drug solanezumab failed to prevent Alzheimer’s in cognitively healthy older individuals who showed amyloid plaque accumulation in…
Scientists still don’t know what causes Alzheimer’s, but they do have one, long-standing theory: the amyloid hypothesis. Some say it’s on the brink of…
The approval of the controversial anti-amyloid drug Aduhelm last year marked a major milestone for Alzheimer’s research — it became the first new drug…